Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer

Phase 2

Conditions: Advanced Head and Neck Cancer

Interventions: Drug: rAd-p53
Radiation: radiation
Drug: Cisplatin

First Posted Date: 2015-04-29

Last Posted Date: 2015-04-29

Lead Sponsor: Shenzhen SiBiono GeneTech Co.,Ltd

Target Recruit Count: 60

Registration Number: NCT02429037

Locations: 🇨🇳
Jiangsu cancer hospital, Nanjing, Jiangsu, China

Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion

Phase 2

Conditions: Malignant Pleural Effusion

Interventions: Drug: rAdp53
Drug: Cisplatin
Drug: rAdp53 plus cisplatin

First Posted Date: 2015-04-29

Last Posted Date: 2015-04-29

Lead Sponsor: Shenzhen SiBiono GeneTech Co.,Ltd

Target Recruit Count: 90

Registration Number: NCT02429726

Locations: 🇨🇳
The First Affiliated Hospital of Xi'an Jiao Tong University, Xian, Shanxi, China

NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB

Phase 3

Not yet recruiting

Conditions: Cervical Cancer

Interventions: Procedure: hysterectomy
Radiation: Radiation
Drug: Cisplatin
Drug: Paclitaxel
Drug: Carboplatin
Drug: Ifosfamide

First Posted Date: 2015-04-21

Last Posted Date: 2015-04-21

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 534

Registration Number: NCT02422563

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Phase 2

Completed

Conditions: Locally Recurrent/Metastatic Triple Negative Breast Cancer

Interventions: Radiation: external beam radiation therapy
Drug: cisplatin
Procedure: Biopsy of Target Tumor

First Posted Date: 2015-04-21

Last Posted Date: 2024-02-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT02422498

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 4 locations

Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Cisplatin
Drug: Cisplatin+TIL

First Posted Date: 2015-04-20

Last Posted Date: 2016-10-18

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 116

Registration Number: NCT02421640

Locations: 🇨🇳
Haiqiang Mai, Guangzhou, Guangdong, China

First Line TIP in Poor Prognosis TGCTs.

Phase 2

Completed

Conditions: Germ Cell Tumor

Interventions: Drug: Paclitaxel
Drug: Ifosfamide
Drug: Cisplatin

First Posted Date: 2015-04-13

Last Posted Date: 2020-08-07

Lead Sponsor: National Cancer Institute, Slovakia

Target Recruit Count: 19

Registration Number: NCT02414685

Locations: 🇸🇰
National Cancer Institute, Bratislava, Slovakia

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Phase 2

Completed

Conditions: High Grade Upper Tract Urothelial Carcinoma

Interventions: Drug: Methotrexate
Drug: Gemcitabine
Drug: Vinblastine
Drug: Carboplatin
Drug: Doxorubicin
Drug: Cisplatin
Drug: Pegfilgrastim
Procedure: Nephroureterectomy

First Posted Date: 2015-04-09

Last Posted Date: 2023-07-10

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 36

Registration Number: NCT02412670

Locations: 🇺🇸
Illinois CancerCare-Canton, Canton, Illinois, United States
🇺🇸
Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸
Illinois CancerCare-Eureka, Eureka, Illinois, United States

and more 131 locations

A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Atezolizumab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2015-04-06

Last Posted Date: 2019-02-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 8

Registration Number: NCT02409355

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States
🇺🇸
Marin Cancer Care Inc, Greenbrae, California, United States

and more 79 locations

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Phase 3

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Drug: Carboplatin
Drug: Cisplatin
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2015-04-06

Last Posted Date: 2023-03-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 572

Registration Number: NCT02409342

Locations: 🇫🇷
Centre D'oncologie de Gentilly, Nancy, France
🇫🇷
Centre Hospitalier Regional Sud Reunion, Saint-pierre, France
🇧🇷
Centro de Pesquisas Clinicas em Oncologia - CPCO, Cachoeiro de Itapemirim, ES, Brazil

and more 139 locations

Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer

Not Applicable

Conditions: Pleural Effusion, Malignant

Interventions: Drug: cisplatin

First Posted Date: 2015-04-03

Last Posted Date: 2015-11-20

Lead Sponsor: Shantou University Medical College

Target Recruit Count: 50

Registration Number: NCT02407912

Locations: 🇨🇳
Department of medical oncology, Shantou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy